Zymeworks (ZYME)
(Delayed Data from NSDQ)
$12.57 USD
+0.38 (3.12%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $12.55 -0.02 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
ZYME 12.57 +0.38(3.12%)
Will ZYME be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZYME
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
3 Top Stocks to Invest in for Amazing Earnings Acceleration
Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for ZYME
Zymeworks Approaching A Moment Of Truth With Zanidatamab
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks to Showcase New Cancer Treatments at Major Conference
Zymeworks’ Hold Rating Amidst Promising Data and Competitive HER2+ GEA Treatment Landscape
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)